CAC Score: Which Tests to Order Alongside Coronary Artery Calcium Screening

What a CAC Score Actually Measures

The CAC score, reported in Agatston units from a non-contrast cardiac CT, quantifies the total burden of calcified atherosclerotic plaque across the left main, left anterior descending, circumflex, and right coronary arteries. It is an anatomical measurement, not a functional one. It cannot tell you why plaque formed, whether inflammation is active, or which metabolic pathways are feeding the process.

In the Multi-Ethnic Study of Atherosclerosis (MESA, N=6,814), participants with a CAC score of 0 had a 10-year coronary heart disease event rate of just 1.1%, while those with CAC >300 had event rates exceeding 10% [1]. The 2019 ACC/AHA Primary Prevention Guideline assigns CAC testing its strongest role in adults at borderline (5-7.5%) or intermediate (7.5-20%) 10-year atherosclerotic cardiovascular disease (ASCVD) risk, where the result can shift the treatment decision toward or away from statin therapy [2]. A score of 0 may allow deferral of statins. A score of 100 or higher generally favors starting them.

But a number alone is incomplete. Dr. Roger Blumenthal, director of the Johns Hopkins Ciccarone Center, has stated: "A CAC score tells you how much plaque is there, but not what's driving it. You need blood work to understand the 'why' behind the calcium." Pairing the scan with targeted labs converts a single data point into a treatment-ready risk profile [3].

Lipid Panel: The Non-Negotiable Companion

Every CAC scan should be accompanied by a fasting or non-fasting standard lipid panel measuring total cholesterol, LDL-C, HDL-C, and triglycerides. This is the minimum requirement. Without it, the CAC score floats in a clinical vacuum.

The reason is straightforward. LDL-C is the primary modifiable driver of atherosclerotic plaque. In the Cholesterol Treatment Trialists' (CTT) meta-analysis of 26 randomized trials (N=170,000), each 1 mmol/L (38.7 mg/dL) reduction in LDL-C lowered major vascular events by 22% [4]. A patient with a CAC of 150 and an LDL-C of 190 mg/dL needs aggressive lipid-lowering. The same CAC in a patient with an LDL-C of 70 mg/dL calls for a different investigation entirely, possibly lipoprotein(a) or inflammatory pathology.

Non-HDL cholesterol, calculated by subtracting HDL-C from total cholesterol, captures VLDL and remnant lipoproteins that LDL-C misses. The 2018 AHA/ACC Cholesterol Guideline identifies non-HDL-C as a secondary treatment target, especially when triglycerides exceed 200 mg/dL [5]. Triglycerides above 150 mg/dL also flag insulin resistance, which links directly to accelerated coronary calcification.

High-Sensitivity C-Reactive Protein (hs-CRP)

hs-CRP measures systemic vascular inflammation and provides risk information that is statistically independent of both LDL-C and CAC score. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced major cardiovascular events by 44% in patients with LDL-C <130 mg/dL but hs-CRP ≥2.0 mg/L [6]. This means inflammation alone, even without classically elevated cholesterol, carries real cardiovascular risk.

When paired with CAC, hs-CRP creates a two-axis framework. A patient with CAC 0 and hs-CRP <1.0 mg/L sits in a very low-risk category. A patient with CAC 50 and hs-CRP of 4.5 mg/L may carry disproportionate risk relative to their plaque burden alone. The MESA study confirmed that adding hs-CRP to CAC improved reclassification of intermediate-risk individuals by 12% [7].

The 2019 ACC/AHA Guideline lists hs-CRP ≥2.0 mg/L as a "risk-enhancing factor" that favors statin initiation in borderline and intermediate-risk patients [2]. Ordering it alongside CAC is clinically efficient: one blood draw, two independent risk axes.

Lipoprotein(a): The Genetic Risk Blind Spot

Lipoprotein(a), or Lp(a), is a genetically determined lipoprotein particle that promotes both atherosclerosis and thrombosis. Approximately 20% of the global population carries Lp(a) levels above 50 mg/dL (the threshold most guidelines consider elevated), and these individuals face a 2- to 3-fold higher risk of myocardial infarction [8]. Lp(a) does not respond to diet, exercise, or statins. It is largely fixed by genetics.

This matters for CAC interpretation because a patient with an unexpectedly high CAC score relative to their traditional risk factors may have elevated Lp(a) as the hidden driver. The European Atherosclerosis Society (EAS) 2022 consensus statement recommends measuring Lp(a) at least once in every adult's lifetime to identify those at genetic cardiovascular disadvantage [9]. The National Lipid Association supports this recommendation.

Dr. Sotirios Tsimikas of UC San Diego, a leading Lp(a) researcher, has noted: "Lp(a) is the most common genetic risk factor for atherosclerotic cardiovascular disease, yet it remains the least tested." A single measurement alongside CAC can reshape a patient's entire risk narrative, particularly for individuals with premature coronary calcification (CAC >0 before age 50) or a family history of early heart disease.

Apolipoprotein B (ApoB)

ApoB counts the total number of atherogenic lipoprotein particles in circulation. Each LDL, VLDL, IDL, and Lp(a) particle carries exactly one ApoB molecule, making it a direct particle count. LDL-C, by contrast, measures the cholesterol mass inside LDL particles only. When triglycerides are high or LDL particles are small and dense, LDL-C can underestimate the true atherogenic burden by 20-30% [10].

The 2021 EAS consensus paper identified ApoB as a stronger predictor of cardiovascular events than LDL-C, particularly in patients with metabolic syndrome, type 2 diabetes, or triglycerides above 150 mg/dL [10]. An ApoB level above 130 mg/dL is considered elevated; below 90 mg/dL is optimal for most adults.

For CAC interpretation, ApoB adds granularity. Two patients with identical CAC scores and identical LDL-C values may have very different ApoB levels, and the one with higher ApoB faces greater future risk. This is especially relevant in patients taking statins whose LDL-C has reached target but whose ApoB remains elevated, a scenario that signals residual particle-driven risk requiring additional therapy such as ezetimibe or a PCSK9 inhibitor.

Fasting Glucose and HbA1c

Diabetes and prediabetes accelerate coronary artery calcification through multiple mechanisms: endothelial dysfunction, oxidative stress, advanced glycation end-products, and chronic low-grade inflammation. In MESA, participants with diabetes had 2.5 times the rate of CAC progression compared to those with normal glucose metabolism over 2.4 years of follow-up [11].

Ordering a fasting glucose (normal <100 mg/dL) and HbA1c (normal <5.7%) alongside CAC accomplishes two things. First, it screens for undiagnosed diabetes or prediabetes, which affects roughly 38% of U.S. adults according to CDC 2022 data [12]. Second, it contextualizes the CAC score. A CAC of 200 in a patient with an HbA1c of 8.1% points toward glycemic control as a priority intervention alongside lipid management. The ADA 2024 Standards of Care recommend cardiovascular risk assessment, including consideration of CAC scanning, for adults with type 2 diabetes who have no known ASCVD but carry additional risk factors [13].

HbA1c also provides a 90-day average glucose window, which is more stable than a single fasting glucose reading. For patients with CAC >0, a concurrent HbA1c reading establishes whether hyperglycemia is contributing to plaque progression.

Thyroid Function (TSH)

Hypothyroidism is an underrecognized accelerator of atherosclerosis. Even subclinical hypothyroidism (TSH 4.5-10 mIU/L with normal free T4) raises LDL-C by 10-15%, increases arterial stiffness, and promotes endothelial dysfunction [14]. The Rotterdam Study (N=1,149 postmenopausal women) found that subclinical hypothyroidism was associated with a 2.3-fold increase in aortic atherosclerosis and myocardial infarction risk [15].

A simple TSH test costs under $30 at most commercial labs. If elevated, it may explain a high LDL-C or an unexpectedly high CAC score in an otherwise healthy patient. Treating the thyroid disorder with levothyroxine can lower LDL-C by 20-30 mg/dL without adding a statin, according to data from a 2017 meta-analysis in the Journal of Clinical Endocrinology and Metabolism [14]. Thyroid function testing is especially relevant for women over 50, who carry a higher prevalence of subclinical hypothyroidism and are also in the age range where CAC screening becomes most informative.

Additional Tests for Selected Patients

Not every patient needs every test. The core panel (lipid panel, hs-CRP, Lp(a), ApoB, HbA1c, TSH) covers most clinical scenarios. However, certain patient profiles warrant additional orders.

Homocysteine. Elevated homocysteine (>15 µmol/L) is an independent risk factor for coronary artery disease. The AHA recognizes hyperhomocysteinemia as a contributing factor to atherosclerosis, though folate supplementation trials have not consistently reduced cardiovascular events [16]. Testing is most useful in patients with premature CAC, a family history of early MI, or B12/folate deficiency risk.

Fibrinogen. This acute-phase reactant and clotting factor reflects both inflammation and thrombotic risk. Levels above 400 mg/dL have been associated with increased cardiovascular events in the Framingham Heart Study. It adds value when hs-CRP is elevated and the clinician wants to distinguish between inflammatory and prothrombotic contributions to risk.

NT-proBNP. While primarily a heart failure marker, NT-proBNP can detect subclinical cardiac stress in patients with high CAC scores (above 400). Elevated levels may prompt echocardiography to evaluate diastolic function or occult ischemic cardiomyopathy.

CIMT (carotid intima-media thickness). This ultrasound-based imaging test measures arterial wall thickness in the carotid arteries and can detect non-calcified plaque that CAC misses. The 2013 ACC/AHA Risk Assessment Guideline gave CIMT a weaker recommendation than CAC for risk stratification, but it remains useful when radiation exposure from CT is a concern or when the clinician suspects significant non-calcified plaque burden [17].

How to Interpret Paired Results: A Clinical Decision Framework

The real value of companion testing emerges when results are read together, not in isolation. A few clinical patterns illustrate this.

CAC 0, normal labs. Extremely low near-term risk. The 2019 ACC/AHA guideline supports deferring statin therapy and repeating CAC in 5-10 years if risk factors remain stable [2]. This combination provides strong reassurance.

CAC 0, elevated Lp(a) or hs-CRP. The CAC may be falsely reassuring. Patients with Lp(a) above 50 mg/dL or hs-CRP above 2.0 mg/L still carry measurable risk despite absent calcification, particularly if they are younger (under 55) and calcification has not yet developed. These patients benefit from aggressive primary prevention with statins and possibly aspirin, depending on the full risk profile.

CAC 1-99, elevated LDL-C and ApoB. This group benefits most from statin initiation. The presence of any coronary calcium in the setting of elevated atherogenic lipoproteins confirms subclinical atherosclerosis and provides a clear indication for pharmacotherapy per the 2018 AHA/ACC Cholesterol Guideline [5].

CAC >100, elevated HbA1c. Dual-target therapy is warranted: lipid-lowering plus glycemic control. GLP-1 receptor agonists such as semaglutide or liraglutide offer cardiovascular event reduction alongside glucose-lowering and weight loss, making them a logical choice in this scenario per the ADA 2024 Standards of Care [13].

CAC >300, any risk factor pattern. This represents extensive coronary atherosclerosis. Refer for cardiology consultation. Consider coronary CT angiography (CCTA) for anatomical characterization of stenosis severity, stress testing for functional ischemia assessment, and aggressive medical therapy including high-intensity statins, ezetimibe, and a PCSK9 inhibitor if LDL-C remains above goal.

How Often to Repeat These Tests

CAC scores do not decrease. Calcification is a one-way biological process under current therapies. Repeat CAC scanning is generally not recommended within 5 years unless a major change in clinical status occurs [2]. The companion blood tests, however, follow standard monitoring intervals.

Lipid panels should be repeated 4-12 weeks after starting or adjusting lipid-lowering therapy, then annually once stable. HbA1c follows a similar pattern: every 3 months during active glycemic titration, every 6-12 months once at goal. hs-CRP can be rechecked after 2-4 weeks if the initial result was elevated, to confirm chronic inflammation rather than an acute infection artifact. Lp(a) requires only one lifetime measurement because its levels are genetically determined and do not change meaningfully with lifestyle or most pharmacotherapy. ApoB should be checked alongside lipid panels, particularly in patients on statins whose LDL-C has reached target. TSH is typically monitored annually in patients with known thyroid disease or every 5 years as a screening test in asymptomatic adults.

The most common error in follow-up is repeating the CAC scan too soon. A rising CAC score does not necessarily mean treatment is failing; increased calcium density within existing plaques may actually reflect statin-mediated plaque stabilization, a phenomenon documented in the SATURN trial [18].